Autolus Therapeutics plc
NASDAQ: AUTLLondon · 2 known investors
Find your way into Autolus Therapeutics plc
Autolus Therapeutics develops engineered T cell therapies targeting cancer and autoimmune diseases using proprietary cell programming technology; the company commercializes AUCATZYL, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and maintains a clinical pipeline evaluating additional indications including pediatric leukemia, lupus nephritis, and multiple sclerosis.
Founders & leadership
MP
Martin PuléSenior Vice President, Founder, Chief Scientific Officer
CW
Christopher WilliamsSenior Vice President, Chief Business Development Officer
CV
Christopher VannExecutive
CI
Christian ItininChief Executive Officer and Director
RD
Robert DolskiSenior Vice President, Chief Financial Officer
PM
Patrick McIlvennyinSenior Vice President, Finance and Chief Accounting Officer
MN
Miranda NevilleinSenior Vice President, Chief Technology Officer
CP
Cintia PiccinainSenior Vice President, US Chief Commercial Officer and Country GMChief Commercial Officer at Adaptimmune
AS
Alexander SwanSenior Vice President, Chief Human Resources Officer
MW
Matthias WillinSenior Vice President, Chief Development Officer
WD
William D. YoungNamed on SEC filing
EB
Edgar BraendleNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$200M disclosed across 1 round · 2024
▶$200MraisedFeb 2024 · 1 investors · OtherRule 506(b)
▶$200MraisedFeb 2024 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Christian ItinExecutive Officer, Director
- William D. YoungDirector
- Edgar BraendleExecutive Officer
- Martin MurphyDirector
- Linda BainDirector
- Christopher VannExecutive Officer
- Martin PuleExecutive Officer
- Cynthia ButittaDirector
- Robert AzelbyDirector
- David BrochuExecutive Officer
- Joseph AndersonDirector
- Robert IannoneDirector
- John BerrimanDirector
- John H. JohnsonDirector
- Elisabeth LeidermanDirector
- Brent RiceExecutive Officer
- Robert DolskiExecutive Officer
- Offering amount
- $200M
- Amount sold
- $200M
- First sale
- Feb 2024
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Autolus Therapeutics plc do?
- Autolus Therapeutics develops engineered T cell therapies targeting cancer and autoimmune diseases using proprietary cell programming technology; the company commercializes AUCATZYL, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and maintains a clinical pipeline evaluating additional indications including pediatric leukemia, lupus nephritis, and multiple sclerosis.
- Who founded Autolus Therapeutics plc?
- Autolus Therapeutics plc was founded by Martin Pulé, Christopher Williams.
- Who are Autolus Therapeutics plc's investors?
- Autolus Therapeutics plc's investors include Nextech Invest, Syncona.
- How much funding has Autolus Therapeutics plc raised?
- Autolus Therapeutics plc has disclosed $200M raised across 1 round.
- Where is Autolus Therapeutics plc headquartered?
- Autolus Therapeutics plc is headquartered in London.